AbbVie (NYSE:ABBV) Stock Gets Price Target Bump from JPMorgan Chase & Co.

Key Points

• JPMorgan raised AbbVie’s price target to $300 from $285 and maintained an “overweight” rating, implying approximately 10.21% upside from the prior close.
• Analyst sentiment remains favorable: AbbVie has a consensus “Moderate Buy” rating and an average price target of $276.64, supported by multiple recent target increases.
• AbbVie exceeded quarterly expectations, reporting $3.65 in earnings per share and $16.99 billion in revenue, while shares traded near their 52-week high at $272.20.

AbbVie (NYSE:ABBV - Get Free Report) had its target price upped by research analysts at JPMorgan Chase & Co. from $285.00 to $300.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective would suggest a potential upside of 10.21% from the stock's previous close.

Other analysts also recently issued reports about the stock. Guggenheim lifted their price objective on shares of AbbVie from $261.00 to $288.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Wells Fargo & Company boosted their price target on shares of AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a research report on Monday, August 17th. Citigroup raised their price objective on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a report on Wednesday, July 15th. BNP Paribas Exane lifted their target price on AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a research report on Tuesday, August 11th. Finally, Sanford C. Bernstein reiterated a "market perform" rating and set a $225.00 target price (up from $203.00) on shares of AbbVie in a report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of "Moderate Buy" and an average target price of $276.64.

AbbVie Stock Performance

ABBV stock traded up $0.84 during mid-day trading on Thursday, hitting $272.20. 4,301,284 shares of the company were exchanged, compared to its average volume of 6,423,691. The firm has a market cap of $480.92 billion, a P/E ratio of 76.89, a P/E/G ratio of 1.22 and a beta of 0.24. The firm's 50 day simple moving average is $258.27 and its 200 day simple moving average is $235.87. AbbVie has a 1-year low of $190.75 and a 1-year high of $274.94.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business's quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts predict that AbbVie will post 13.93 EPS for the current fiscal year.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

Institutional Trading of AbbVie

Several institutional investors and hedge funds have recently bought and sold shares of the business. Ranch Capital Advisors Inc. lifted its position in shares of AbbVie by 37.0% in the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company's stock worth $3,238,000 after purchasing an additional 4,017 shares during the period. Capital Advisors Inc. OK increased its position in shares of AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company's stock worth $112,516,000 after buying an additional 45,132 shares during the period. Danica Pension Livsforsikringsaktieselskab bought a new position in AbbVie during the second quarter worth $23,557,000. Wedge Capital Management L L P NC raised its stake in AbbVie by 7.5% during the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company's stock worth $33,865,000 after buying an additional 9,380 shares during the last quarter. Finally, Mission Wealth Management LP lifted its holdings in AbbVie by 119.1% in the second quarter. Mission Wealth Management LP now owns 69,052 shares of the company's stock valued at $17,376,000 after buying an additional 37,531 shares during the period. Institutional investors own 70.23% of the company's stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Temab-A received two FDA Breakthrough Therapy Designations. The designations cover colorectal cancer and non-small cell lung cancer. They may accelerate development and regulatory review for telisotuzumab adizutecan, AbbVie’s investigational c-Met-directed antibody-drug conjugate, although they do not guarantee approval or commercial success. AbbVie’s Temab-A Receives Two Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 data for Epkinly could expand AbbVie’s hematologic-cancer opportunity. AbbVie and Genmab said epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly in frontline treatment. AbbVie and Genmab Phase 3 Epkinly Data
• Positive Sentiment: Cantor Fitzgerald raised its price target from $285 to $290 and maintained an “overweight” rating. The target increase reflects continued analyst confidence in AbbVie’s pipeline and earnings outlook. Why Is AbbVie Stock Trending After Hours?

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.